BEACON introduced another promising multikinase inhibitor, Lenvatinib, under the brand name of Lenvanix for global market.

Lenvatinib is an anticancer drug. It is the

  • First new Front-Line treatment option for Hepatocellular Carcinoma (HCC) approved in Japan in nearly 10 years.
  • First TKI to demonstrating Complete Response (CR) in a phase 3 trial for locally recurrent or metastatic, progressive RAI-refractory Differentiated Thyroid Cancer (DTC):
  • Lenvatinib plus everolimus is the first and only FDA-approved regimen for advanced Renal Cell Cancer (RCC) treatment in the past decade
  • Once daily oral dose

Lenvanix is an oral capsule preparation which is available in the strengths of 10mg & 4mg. Each pack of Lenvanix contains 30 capsules.

To know more visit